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Introduction
Transplantation is a relatively new medical specialty,
dating back to only 1954 when Dr Joseph Murray
took a kidney from a living identical twin and placed
it into the other.1 A period of 8 years elapsed before the
first successful cadaveric transplant was performed by
Dr Murray in 1962.2 After this landmark cadaveric
kidney transplant, there was a rapid development in the
number and type of transplant procedures. The first
successful single lung transplant was performed by
James Hardy at the University of Mississippi in 1963,
while Thomas Starzl and Christian Barnard performed
successful liver and heart transplants in 1967.3,4 How-
ever, the medical community did not initially accept
transplantation as a viable treatment for end-stage organ
disease because postoperative outcomes were poor due
to organ rejection. The introduction of cyclosporine
in 1983 changed how the medical community viewed
transplantation.5 As postoperative survival steadily im-
proved, the field of solid organ transplantation entered
into modern medical care.
The field of transplantation rapidly developed a
solid scientific compendium of evidence over the last
50 years to support its medical practice patterns. The
cumulative scientific knowledge became so extensive
and diverse that physicians had to specialize in specific
organ systems. Medical specialties such as surgery,
cardiology, pulmonary medicine and hepatology cre-
ated separate credentialed programs in the field of
transplantation to ensure that physicians had reached
a documented level of competence. The knowledge
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required for perioperative care was also unique even
though these specialists have never established specific
credentials.6
The first anesthesiologists to care for transplant
recipients in the operating room were trained in the
field of intensive care. These physicians had a broad
experience caring for the critically ill. They also had a
diverse knowledge and skill set that made them more
comfortable caring for critically ill liver transplant
recipients in the operating room. As postoperative
outcomes improved, intensive care training was no
longer considered essential for the intraoperative care
of transplant recipients and new generations of liver
transplant anesthesiologists were most often infor-
mally trained by their predecessors. This approach
propagated a tradition of perioperative practices that
tend to be center-specific, with local, regional and
even national differences in practice patterns between
transplant centers worldwide.7 The significant differ-
ences observed in perioperative resource utilization
are easily explained by the diverse approach to patient
management.8 Adhering to institution-specific prac-
tices may explain why the evidence to support specific
perioperative practices continue to lag behind the
other transplant-related specialties. However, there is
a new interest in sharing information about anesthesia-
related practices across institutional boundaries.9 As 
a result, studies that assess the risks and benefits of 
the different perioperative practices are now emerg-
ing. This review will explore the unique forces that
created differences in perioperative practices using a
historic perspective. We will track the evolution of
specific anesthesia transplant practices and examine
some of the scientific challenges that transplant 
anesthesiologist continue to face as their specialty
matures.
The Control of Blood Loss in Liver
Transplantation
The clinical practice of liver transplantation is built
upon the scientific evidence from multiple medical spe-
cialties. Advances in 1 subspecialty of liver transplanta-
tion have wide reaching effects on practice patterns in
the other related specialties. This is particularly true for
surgery and anesthesia. This is clearly seen in the early
history of transplantation when surgeons were devel-
oping their technical approach. Surgeons initially con-
structed a portocaval shunt to maintain venous return
during the anhepatic stage and they performed a
splenectomy to assist in immunosuppresion.10 These
procedures were performed in patients who were so
ill that they were close to death. The combination 
of extensive surgery in critically ill patients caused
bleeding that was so severe that it was almost con-
sidered an insurmountable obstacle to survival. In
response, anesthesiologists developed tools that rap-
idly administered warm blood to prevent exsanguina-
tions during surgery. They modified cardiopulmonary
bypass pumps to create the first rapid infusion devices.11
These “new pumps” were able to meet the transfusion
needs of most patients while preventing hypothermia.
This step alone made the surgical procedure possible
because it significantly improved a patient’s chance of
intraoperative survival.
Blood loss has always been a central issue in liver
transplantation.12 It remains a major cause of morbid-
ity and mortality even though death due to intraoper-
ative hemorrhage is increasingly rare. This is because
blood transfusion is independently correlated with
negative outcomes in liver transplantation, an obser-
vation that occurs in other types of surgery.13 The
risks associated with transfusion have always been the
principal factor that motivated technical refinements in
surgical technique.14 Two major events significantly
reduced intraoperative blood loss. First, surgeons
abandoned the construction of portocaval shunts in
favor of the use of venovenous bypass circuits.15 This
essentially “externalized” the portocaval shunt and
reduced the amount of tissue trauma and therefore
bleeding. Second, the introduction of cyclosporine
reduced the need for splenectomy.16 The resulting fall
in blood transfusion translated directly into better
outcomes for the patients.
The average blood loss can be used to track the
historical changes in surgical technique. In the late
1980s, an average transfusion of 20 units of packed red
blood cells were used for each procedure compared to
the average of 2 units of blood used in 2003.13
Investigators from a single institution reported a sig-
nificant reduction in the use of blood products.17 In
fact, they reported that up to 79% of their patient
population did not need any red cell transfusion dur-
ing surgery.18 However, there has always been a large
variability in the amount and type of blood products
used between transplant centers for patients with sim-
ilar demographics and intraoperative characteristics.18
The amount of blood used is determined by the
amount lost due to surgical technique and transfusion
triggers used by anesthesiologists. It is difficult to
separate the effects of these 2 important factors.
However, it is likely that institution-specific anesthesia
practices explain some of the variability in blood uti-
lization.19 This suggests that evidence-based proto-
cols that specifically guide intraoperative transfusion
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during transplantation could minimize some of the
institutional variation and improve outcome.12
The next wave of changes that reduced blood loss
and improved patient outcomes came from advances in
the anesthesia management of the systemic circulation
during surgery.20,21 Circulatory instability was common
during surgery and placed patients at risk of ischemic
injury. Anesthesiologists found that they could use
vasoconstrictors to increase systemic vascular resis-
tance during surgery, which in turn improved blood
pressure and organ perfusion.22 Anesthesiologists also
borrowed techniques from the field of hepatology that
specifically controlled splanchnic blood flow.23 Anesthe-
siologists discovered that intra-abdominal blood loss
would be reduced by limiting splanchnic blood flow
during surgery.20 Drugs used to control variceal bleed-
ing such as vasopressin are now commonly used during
surgery to selectively limit blood flow to the gut in
order to reduce surgical bleeding.24 Control of the
circulatory system made the use of venovenous bypass
optional.25 This reduced the anhepatic time, along
with the cold ischemic and total surgical time—factors
that are strongly correlated with outcome.26 These
changes should improve outcome; however, there is
still no consensus on the surgical management of the
anhepatic stage, whether it is beneficial or not to use
venovenous bypass with the piggyback technique or
total vascular exclusion because large randomized
studies have not yet been performed. Thus, while a
large number of centers have abandoned venovenous
bypass circuits, some centers continue to use them.
There is clear evidence from studies of elective
hepatic resection that anesthesia manipulation of cen-
tral venous pressure during surgery can reduce blood
loss.27 Investigators have presented convincing evi-
dence that lowering the central venous pressure by
restricting fluid administration or inducing diuresis
can decrease transfusion requirements.28,29 Investiga-
tors also think that a lower central venous pressure
can improve oxygen delivery to the donor graft. A low
central venous pressure would create a venous pres-
sure gradient between the portal and central venous
circulation that draws blood through the donor graft.
Despite this convincing evidence, individual centers
still debate the benefits and risks of lowering central
venous pressure because there are no outcomes stud-
ies with a matched control group to evaluate the spe-
cific effects on liver transplant recipients. Some also
point out that there is no evidence to help the anes-
thesiologist identify an actual pressure measurement
that constitutes a low central venous pressure or
whether 1 value works equally well in a diverse popu-
lation. Concerns are expressed about what central
venous pressure is beneficial and what value could
place a patient at an increased risk of organ injury.17,30
There is least agreement between anesthesiologists
about how to manage coagulation in the operating
room. Early in the history of liver transplantation,
anesthesiologists adapted coagulation monitoring for
use inside the operating room so that they could rap-
idly obtain objective data to make impartial decisions
about blood transfusion.31 Many anticipated that rou-
tine monitoring of the coagulation system during sur-
gery would standardize the transfusion of all blood
products and therefore reduce the variability in blood
administration between institutions.32 To date how-
ever, anesthesiologists are still seeking a “gold stan-
dard” to monitor coagulation. Consequently there is
little agreement about what laboratory values should
trigger an intervention. There are proponents for the
use of different coagulation monitoring modalities
including thromboelastography (TEG), Sonoclot analy-
sis, and standard laboratory tests including prothrom-
bin time and partial thromboplastin time.31,33,34 Their
impact on transfusion management has not yet been
reported for either single institutions or compared
across institutions.
In a similar manner, there have always been pro-
ponents for and against the prophylactic use of phar-
macological agents that are thought to stabilize clot
formation and therefore reduce blood loss.35,36 The
routine use of prophylactic antifibrinolytic drugs was
common in the early history of transplantation, but
many care providers no longer adhere to this practice
because of recent reports of thrombotic complica-
tions.37,38 Physicians question if the number of throm-
botic episodes is increasing. However, the context in
which physicians view the balance of the risks and
benefits of such drugs has been tipped by the changes
in transfusion practices. Massive transfusion is associ-
ated with a high mortality and thus any risk associated
with the prophylactic use of antifibrinolytic agents
appears small. However, these risks appear magnified
in patients who use very little blood since thrombotic
complications become a larger proportion of the nega-
tive outcomes. The relative blood loss each center expe-
riences will thus influence the decision of whether to
use drugs prophylactically that stabilize blood clots.
The Effects of Organ Availability on
Transplant Practices
The number of liver transplants performed worldwide
increased significantly from 1988 to 2006. The lack
of donor organs is the single factor that controls the
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growth of transplantation worldwide. This single issue
is 1 of the most influential determinants of how trans-
plant practices adapt and develop.39 Physicians identi-
fied at least 3 novel ways to expand the organ pool in
order to reduce the number of deaths on the trans-
plant waiting list. All 3 approaches had a significant
influence on how transplant practices developed. The
first change was to create an objective method to allo-
cate organs to patients on the waiting list. The second
approach was to expand the donor pool by using donor
organs that have a higher risk of graft failure. And the
third was to use organs from living donors.40,41
Policies that administer organ allocation are 1 of the
most important factors that have affected anesthesia
liver transplant practices.42 Waiting time was an impor-
tant factor in organ allocation in many countries dur-
ing the latter half of the 1990s.43 This allowed patients
who were less ill to reach the top of the waiting list.
During this time, there was a fall in total resource uti-
lization coupled with an increase in 1- and 5-year life
expectancy.44 Studies showed that the majority of
resources had previously been consumed in high acuity
care following liver transplantation.45 In fact, intensive
care unit charges accounted for up to 1 quarter of all
costs for a transplant admission. The fall in severity of
patient illness coupled with advances in fluid and
coagulation management opened a window of oppor-
tunity that allowed anesthesiologists to specifically
reduce the use of costly perioperative resources. Inves-
tigators were able to contain costs by introducing par-
adigms that reduced the use of routine postoperative
ventilation.46 This in turn reduced intensive care unit
length of stay.47,48 Of these protocols, immediate post-
operative extubation proved to be very cost-effective
and has been a growing trend amongst transplant
centers throughout the world.
In February of 2002, the model for end-stage liver
disease (MELD) and its pediatric equivalent (PELD)
replaced previous policies for donor organ allocation in
the United States.49 Prior allocation policies included
patient variables that required subjective assessment.
Factors such as the severity of ascites or encephalopathy
were subject to varying impression between observers.
The MELD score aimed to objectify the criteria used
to prioritize candidates for liver transplantation by
generating a numerical score from the 3 standard lab-
oratory values of international normalized ratio (INR),
serum bilirubin and creatinine.50 And, the sole aim of
MELD was to transplant the patient with the highest
score, i.e. patients with the greatest mortality risk.
Although the intent of MELD is to transplant the
sickest patients first, the actual MELD score does not
necessarily correlate with the severity of illness due to
liver disease. For example, patients can receive addi-
tional MELD points for conditions such as hepatocel-
lular cancer and hepatopulmonary syndrome. The
number of points given is based on the predicted
mortality without transplantation. Many countries
have not adopted the formal use of MELD as an allo-
cation tool, but it has become an international currency
to exchange information about outcomes. Further,
there is a trend in the international liver transplant
community to adopt the practice of transplanting
patients with a greater severity of illness, similar to the
aim of MELD.
Deaths on the waiting list have fallen by 10% in the
United States since MELD was implemented,51 but the
patients who present for liver transplant have a much
greater severity of illness and consume significantly
more resources.52 This is shown by the correlation
between the MELD score, blood use and the need for
vasopressor support in the operating room; factors
that are all associated with negative outcomes.53,54 In
addition, the inclusion of creatinine in the MELD
score has shifted the priority for transplantation to
patients with renal insufficiency or failure. Physicians
have elected simultaneous liver-kidney transplantation
(SLK) more often since the introduction of MELD55
because long-term outcomes are inferior in patients
who need dialysis following liver transplantation.56,57
However, a recent analysis showed that outcomes from
SLK are not always better than liver transplantation
alone.58 Investigators think that the preferential allo-
cation of kidneys to older and more critically ill patients
with renal dysfunction explain the poor long-term
outcomes observed following SLK.58 Anesthesiologists
therefore now care for more critically ill patients with
renal dysfunction. There is no evidence-based consen-
sus on how to manage fluid and electrolyte abnormal-
ities in patients with renal dysfunction or frank failure.
Investigators have described successful intraoperative
management with ultrafiltration and hemodialysis.59,60
In a study of 11 SLK patients, 4 received hemodialy-
sis, 1 ultrafiltration and both techniques were used in
3 patients.60 No form of renal replacement therapy
was used in 3 patients. This study clearly showed that
renal dysfunction can be managed in the operating
room by more than 1 approach. However, it is still not
clear what the indications for renal replacement therapy
are, what the goals of therapy are, and which therapy
will benefit the patient the most. Further evidence is
needed to address these issues.
Investigators continue to adapt the MELD score to
the changing pattern of indication for transplantation.
The most current proposal adds serum sodium to the
MELD formula since a value <126 mmol/L at the time
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of listing is associated with a 6.3–7.8 fold increased
risk of death.61 The higher priority of patients with renal
failure and low serum sodium challenges anesthesiolo-
gists to identify the best ways to preserve renal function.
Although the MELD score continues to evolve, the
philosophy is consistent: transplant the sickest patient.
This is a significant factor that will continue to shape
perioperative practices in the USA.
The second approach to solving the organ short-
age uses organs from donors who have a higher risk of
graft failure in the recipient. Studies have identified a
number of donor risk factors that predict a greater
risk of organ failure.62 These include donor age >60,
death due to cerebrovascular disease or comorbid sys-
temic illness such as diabetes.63 There is also a greater
risk of donor graft failure associated with organs that
are split between 2 recipients and those recovered from
donors who have died a cardiac death. The collective
group of characteristics that increase the risk of graft
failure is called extended criteria donors (ECD). The
expansion in the use of ECD donors occurred at the
same time that the severity of patient illness increased.
This has created a situation of double jeopardy. Inves-
tigators are just beginning to weigh the full effects of
combining high-risk recipients with high-risk donor
organs.64 There is compelling evidence that both higher
MELD scores and the use of ECD are associated with
greater perioperative cost. The trend to stretch the
donor pool farther in sicker patients may therefore
impact total resource utilization. The increased risk of
delayed donor graft function or even primary non-
function will have its greatest impact on the type of
care and resources used for perioperative care.
Recovering the right or left lobe of the liver from
living donors is the third practice that has eased the
organ shortage. Most adult living donor transplants
done in the USA use the right lobe of the liver. In con-
trast, the left lobe is commonly used in small adults in
Asia and in most pediatric patients. There was very 
little interest in living liver donation in the USA after
the first procedure was performed in 1991.65 The
enthusiasm for living liver donation, however, increased
as cadaveric donor organs became increasingly scarce.
The growth of living donor liver transplantation
peaked in the USA in 2001 with 522 cases performed
and has steadily declined with only 265 cases com-
plete in 2007.66 In contrast, living donation is a pri-
mary source of organs for patients in Asia.67,68 The
number of cases in Japan and Taiwan alone far
exceeds those performed in the United States. The
decline in living donor liver transplantation coincided
with the death of a living liver donor in 2005. In the
USA, over 1,700 living donor liver transplants have
been performed with 2 early deaths and 2 liver trans-
plants in adult donors.69 However, other factors have
played a role in causing the decline of living liver
donation. These include: changes in organ allocation
that prioritize medical urgency; exhaustion of the ini-
tial pool of eligible patients on the waiting list, leaving
only new additions to the waiting list as potential liv-
ing donor transplant candidates; and the increasing
use of extended criteria (marginal) donors.69 The use
of alternate donor sources has forced anesthesiologists
to step out of their traditional role where they only
focus upon the recipient. They now must take on new
responsibilities to facilitate the unique interaction
between the live organ donor and transplant recipient.
Conclusion
The art and science of perioperative liver transplanta-
tion has undergone a remarkable evolution since its
humble beginnings in 1967. Perioperative physicians
have been instrumental in improving liver transplant
recipient outcome and adapting their practice to the
progress in other aspects of transplant practice. But
there is still considerable debate about the relative
benefits and risks of many anesthesia-based practices.
The informal apprenticeship that anesthesiologists use
to train their successors may inadvertently reinforce the
difference in practice patterns between institutions.
This creates a widening gap between institutional pref-
erences and evidence-based practices. The trend in the
USA and other countries is to transplant the sickest
patients while using organs at risk for graft failure. With
impending constraints on resource utilization world-
wide, anesthesiologists have to examine their practices
beyond the limits of institutional boundaries to identify
those that are associated with the best outcome while
being cost-effective.
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